CRP and breast cancer: We have shown that circulating biomarkers of inflammation, hypercoagulability, and endothelial injury, including C-reactive protein (CRP), thrombomodulin (TM), and thrombin–antithrombin complex (TAT), correlated with the risk of DOX-induced cardiotoxicity in breast cancer patients [41].